Bladder cancer patients get new hope from virus therapy

NCT ID NCT07505615

Completed Disease control Sponsor: Ding-Wei Ye Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment called VG161, a virus designed to attack cancer cells, in 20 people with a type of bladder cancer that didn't respond to standard therapy. The virus was given directly into the bladder through a tube. The goal was to see if it is safe and if it can help prevent the cancer from coming back. The trial has been completed, and the results will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VG161 (a modified virus that targets and kills cancer cells)
What this could lead to: If it works, this could offer a new treatment option for people with bladder cancer that hasn't responded to standard therapy.
What could go wrong: This is an early-phase trial with only 20 patients, so results may not apply widely. The virus may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMIBC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMIBC

Contacts and locations

Locations

Fudan University Shanghai Cancer Center, ShangHai,

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.